Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 13;11:806243. doi: 10.3389/fonc.2021.806243

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Watts, Lin, Mims, Patel, Lee, Shahidzadeh, Shami, Cull, Cogle, Wang and Uckun

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Depletion of Circulating CD123⁺CD34⁺CD38^- and CD33⁺CD34⁺CD38^- Cells in VENAZA-resistant Relapsed AML Patient Receiving APVO436 Monotherapy. The numbers in the left upper corner in the first 2 columns represent the total CD34⁺CD38^- cell numbers of which the vast majority co-expressed both CD123 and CD33. Panels (A–D) show the results at specific study time points: (A) C1D1 = Cycle 1, Day 1; (B) C2D15 = Cycle 2, Day 15; (C) C4D1 = Cycle 4, Day 1; (D) C6D1 = Cycle 6, Day 1. Virtually all the CD34⁺CD38^- cells were CD123⁺ and CD33⁺ consistent with AML. The size of this CD123⁺CD33⁺CD34⁺CD38^- AML blast population indicated with the arrow in Panel (A), 3^rd column, was significantly reduced by APVO436 monotherapy. See also Table 2 .